Combined radiotherapy and concurrent tumor treating fields (TTFields) for glioblastoma: Dosimetric consequences on non-coplanar IMRT as initial results from a phase I trial

BACKGROUND: Glioblastoma is a rapidly proliferating tumor. Patients bear an inferior prognosis with a median survival time of 14-16 months. Proliferation and repopulation are a major resistance promoting factor for conventionally fractionated radiotherapy. Tumor-Treating-Fields (TTFields) are an ant...

Descripción completa

Detalles Bibliográficos
Autores principales: Guberina, N., Pöttgen, C., Kebir, S., Lazaridis, L., Scharmberg, C., Lübcke, W., Niessen, M., Guberina, M., Scheffler, B., Jendrossek, V., Jabbarli, R., Pierscianek, D., Sure, U., Schmidt, T., Oster, C., Hau, P., Grosu, A. L., Stuschke, M., Glas, M., Nour, Y., Lüdemann, L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7168823/
https://www.ncbi.nlm.nih.gov/pubmed/32307022
http://dx.doi.org/10.1186/s13014-020-01521-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7168823/
https://www.ncbi.nlm.nih.gov/pubmed/32307022
http://dx.doi.org/10.1186/s13014-020-01521-7

Ejemplares similares